Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

"Inovio Pharmaceuticals Inc. has spent years developing a DNA-based vaccine platform. Its first product and lead candidate, VGX-3100, is for cervical intraepithelial neoplasia, a precancerous condition resulting from infection with the human papillomavirus. VGX-3100 is a synthetic, circular DNA molecule that acts like a virus. It comes into the body enabled by electroporation, an electrical shock applied to the skin with the injection. It hooks onto the cell surface and injects its DNA into the cell, which is what a virus does in vector-guided gene therapy. It then takes over the cellular translation or protein synthesis machinery, and directs the production of antigens, which are proteins, just as they were encoded in the plasmid. It allows the body to attack four proteins found on HPV virions. The idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating. . ." read more >

Yi Chen, H.C. Wainwright & Co. (3/17/15)
"Inovio Pharmaceuticals Inc. reported yesterday its Q4/14 and FY14 financial results. Total revenues for Q4/14 were reported at $2.5M, slightly higher than our projection of $2.2M. . .for FY14, total revenues and EPS were $10.5M and ($0.64)/diluted share, respectively. . .we reiterate our Buy rating."

Jason Kolbert, Maxim Group (3/17/15)
"Inovio Pharmaceuticals Inc. reported Q4/14 and FY14 results, with $2.5M and $10.5M in recognized contract revenue. . .the company ended the year with $94M in cash. . .Inovio plans to move VGX-3100 into a Phase 3 trial by itself versus waiting for a partner."

Charles Duncan, Piper Jaffray & Co. (3/16/15)
"Inovio Pharmaceuticals Inc. reported FY14 results, ending the year with cash equivalents of $93.6M. . .clinical programs are advancing well, in line with expectations. The company also announced a $16M grant (over five years) from the National Institute of Allergy and Infectious Diseases to further develop the Pennvax HIV vaccine program."

Yi Chen, H.C. Wainwright & Co. (3/12/15)
"We are initiating coverage of Inovio Pharmaceuticals Inc. with a Buy rating and a 12-month price target of $17.00 per share. . .a highly diversified developer of differentiated DNA-based synthetic vaccines. . .a novel and highly effective way to treat various infectious and oncology-focused disorders. The company also possesses an electroporation delivery system that is known to enhance the effectiveness of DNA vaccines. . .Inovio has a lean operation and employs a business model in which it utilizes its technology platform to produce a steady stream of potential product candidates. . .tested in early-stage and proof-of-concept clinical trials, after which Inovio may seek partners."

Charles Duncan, Piper Jaffray & Co. (3/5/15)
"Inovio Pharmaceuticals Inc. recently presented updated data from the Phase 2 for VGX-3100 for cervical dysplasia that we view as being positive but that may have been overlooked by investors. We think the data are an excellent illustration of the power of electroporation plus SynCon constructs to drive effective T-cell responses and, in this case, significant reductions in viral levels; this is but the tip of the iceberg for the company's burgeoning pipeline."

Management Q&A: View From the Top
J. Joseph Kim
Inovio Pharma- ceuticals Inc. (INO:NYSE.MKT) is in the forefront of developing DNA vaccines, inserting engineered genes into cellular machinery to synthesize proteins that, in turn, generate antibodies that fight disease. If pivotal studies read out favorably, DNA immunization could prove a true game changer in healthcare. In this interview with The Life Sciences Report, Inovio President and CEO J. Joseph Kim discusses his company's platform technology, which addresses both therapeutic and preventive methods of fighting disease.
read more >

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content